Abaloparatide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Abaloparatide |
| DrugBank ID | DB05084 |
| Brand Names (EU) | Eladynos |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.84% |
Approved Indication (EMA)
Treatment of osteoporosis in postmenopausal women at increased risk of fracture.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | non-syndromic esophageal malformation | 99.84% | DL |
| 2 | esophageal disease | 99.75% | DL |
| 3 | amenorrhea (disease) | 99.72% | DL |
| 4 | esophageal ulcer | 99.02% | DL |
| 5 | migraine disorder | 98.88% | DL |
| 6 | migraine with brainstem aura | 98.75% | DL |
| 7 | severe nonproliferative diabetic retinopathy | 98.09% | DL |
| 8 | pseudo-von Willebrand disease | 97.42% | DL |
| 9 | primary release disorder of platelets | 97.38% | DL |
| 10 | biotin metabolic disease | 97.27% | DL |
| 11 | esotropia | 97.24% | DL |
| 12 | injury | 97.20% | DL |
| 13 | vitamin deficiency disorder | 96.80% | DL |
| 14 | Glanzmann thrombasthenia | 96.69% | DL |
| 15 | Raynaud disease | 96.37% | DL |
| 16 | duodenal ulcer (disease) | 96.17% | DL |
| 17 | radiation or chemically induced disorder | 96.12% | DL |
| 18 | segmental odontomaxillary dysplasia | 96.09% | DL |
| 19 | florid cemento-osseous dysplasia | 96.09% | DL |
| 20 | perinatal disease | 96.09% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.